Corrigendum to 'Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States': [ESMO Open Volume 6, Issue 5, October 2021, 100252]
ESMO Open. 2021 Dec;6(6):100286.
doi: 10.1016/j.esmoop.2021.100286.
Epub 2021 Oct 19.
1 University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, CWRU School of Medicine, Cleveland, USA. Electronic address: jain.prantesh@gmail.com.
2 Layer 6 AI, Toronto, Canada.
3 Harrington Heart and Vascular Institute, Cleveland, USA.
4 Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, USA.
5 Research and Education Institute, University Hospitals Health System, Cleveland, USA.
6 Department of Medical Oncology, City of Hope, Duarte, USA.
7 ImmunoOncology Branch, Developmental Therapeutics Program, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, USA.
8 Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, USA.
9 Department of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, CWRU School of Medicine, Cleveland, USA; Research and Education, University Hospitals Health System, Cleveland, USA.
10 University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, CWRU School of Medicine, Cleveland, USA.